Dr. iris good

Dr. iris good

She is the Scientist-entrepreneur and investor, Iris specializes in commercialization of healthcare technologies in international markets for over 20 years, focusing on the Indian market. Iris chairs Good Relations India, the Imperial College Enterprise Seed Fund, the London Business School HealthTech Challenge, a member of the investment committee of Cambridge University Seed Fund and a trustee of Weizmann-UK Board. She has recently joined the Advisory Council of Martlet Capital, a Cambridge-based early stage investment Fund. 

Soon after completion of her Ph.D. in Biochemistry from the Weizmann Institute of Science, followed by two post docs (molecular biology and brain research), Iris co- established UltraShape and developed the first FDA-approved and commercially-used non-invasive aesthetic ultrasound procedure. The company was acquired by Syneron Medical Ltd ($12M). She then led the business development of MetaCure, a minimally- invasive diabetic pace-maker, which she took to India, setting up pan-India clinical-trials and commercial operations. She founded I-Connections, an India market-entry firm focusing on cutting edge healthcare technologies, establishing strategic partnerships and commercial expansions. I-Connections later merged with Good Relations India, a 34- years old award-winning Strategic PR & Market Entry consultancy with offices in India and London, providing full market-entry strategy and execution to international corporates in India, becoming its chair in 2008. 

Good Relations India has advised leading clients such as Apple, Barclays, Bloomberg, Cartier, CNBC, Etihad, The UN and Virgin Atlantic together with hundreds of start-ups. The company brought Marks & Spencer to India and created their JV with Reliance Industries, Sun Life Insurance with Birla Group, Scottish & Newcastle with Kingfisher and many others. Iris has served on the boards of Sight Diagnostics, Step of Mind and Tikal Networks (Israel) on the advisory board of Trapezia Capital and Puridify Ltd and on the main board of Accloud and Touchlight Genetics (UK). She has been active mentor/judge/investor in London Business School, Judge Business School, Oxford Foundry and Imperial College. She has been a member of the Cambridge Seed Fund investment committee since 2018 and has chaired the Imperials College Seed Fund since 2020 and has been a trustee of Weizmann-UK since December 2021. A dear Soul Sister who aspires to enable accessible and affordable medical care for all.